Roivant Sciences and Roivant Social Ventures Provide Internship Opportunities for Talented PharmD Students

Roivant Sciences, Roivant Social Ventures (RSV), and Elutia have partnered to create summer internship opportunities to provide real-world drug development experience to talented PharmD students. The intentions of this program are to expand access to medicines to underserved populations, and to further UNC Eshelman School of Pharmacy's goal of providing future industry leaders with pharmaceutical experience during their PharmD tenure.

Reflecting on her experience as Roivant's 2023 Research and Development Intern, Hannah Summers shared, “This experience has been nothing short of transformative. I have had the chance to delve into the various components of a pharmaceutical quality system, such as the importance of regulatory history and inspections, supplier qualification, and review of controlled documents, while witnessing the development of life-changing drugs, and actively participating in various aspects of the drug development process. These hands-on experiences have fostered a deeper understanding and appreciation for the work and dedication it takes to develop innovative medications.”

We congratulate the following talented students on their 2024 internships:

  • Derek Bassett, Corporate Strategy Intern with Elutia, a biotech company led by RSV Advisory Board member Randy Mills. Elutia focuses on a proprietary drug-eluting biomaterial platform that stands at the forefront of medical innovation.

  • Amanda Bowlin, Regulatory Strategy Intern with Roivant Sciences.

  • Mackenzie Greene, RSV Global Access Fellow, volunteering with Goodlife Access and Goodlife Pharmacy in Rwanda, Africa. 

  • Ethan Hsu, Chemistry, Manufacturing, and Control (CMC) Intern with Roivant Sciences' Research and Development (R&D) team.

  • Magdalene Mallory, RSV Global Access Fellow, volunteering with Goodlife Access and Goodlife Pharmacy in Rwanda, Africa. 

During the Spring 2024 semester all interns completed RSV's "Making Medicines" course, described in more detail below. 


Roivant Social Ventures "Making Medicines" Course at the UNC Eshelman School of Pharmacy

During the Spring 2024 semester RSV taught "Making Medicines" at the UNC Eshelman School of Pharmacy, the top ranked School of Pharmacy in the United States. This innovative course was designed to introduce PharmD students to the new drug approval process and key issues in drug discovery, pre-clinical testing, clinical trials, FDA approval, and global access to medicines. The course is taught by Lindsay Androski, RSV Founder & CEO, and Scott Singleton, Associate Professor at the UNC Eshelman School of Pharmacy.

We would like to send a gracious thank you to our expert guest lecturers: 

  • John Cox, Founder & Former CEO of Bioverativ (now part of Sanofi)

  • Anuj Hasija, Former VP of Global Marketing at Novartis Oncology 

  • Dan Patterson, VP & Head of CMC, Biologics & Gene Therapies at Roivant Sciences & RSV Board Member

  • Steve Piscitelli, PharmD, VP and Head of Clinical Development at Dermavant

  • Clifford Samuel, Former SVP of Access Operations & Emerging Markets at Gilead Sciences & RSV Advisory Board Member

  • Woody Sherman, Founder & CEO of Psivant

  • Jane Sohn, Staff Director of Nonprescription Drugs Pharmacology-Toxicology Staff, Office of Nonprescription Drugs, FDA

  • Bill Symonds, PharmD, Co-Founder of Pharmasset (now part of Gilead Sciences)  & Co-Founder of Roivant Sciences

It was a pleasure having these dynamic professionals share their real-world insights to inspire the next generation of PharmD leaders!

Previous
Previous

2024 Access to Medicines Internship Spotlight

Next
Next

Roivant Social Ventures Launches Inaugural Convergence Forum Fellowship Program